Results Report 2026
The 2026 Results Report captures a defining moment in the fight against AIDS, tuberculosis (TB) and malaria.
2025 was a year of seismic change in global health. Abrupt and far-reaching cuts in international financing, combined with other shocks, placed enormous pressure on health programs and systems around the world, threatening decades of progress against some of the deadliest infectious diseases. Yet countries, communities and partners responded with determination, resilience and innovation.
The Global Fund partnership was at the center of that response. We worked with countries to protect essential services, accelerate access to breakthrough technologies and focus resources where they could save the most lives. Across HIV, TB and malaria programs, we supported countries as they adopted new approaches, strengthened integration and prioritized the people and communities most at risk.
The results in this report demonstrate what is possible when countries lead, communities are at the center of decision-making, and partnership remains focused on impact. Our results also underscore an important lesson: Progress can never be taken for granted. Sustaining and accelerating gains against HIV, TB and malaria will require continued investment, innovation and collective action.
Key Results and Lives Saved
Key Results
Programmatic results achieved during 2025 by countries and regions where the Global Fund invests. Global Fund Regional Groupings.
Since 2002, coverage of key HIV, TB and malaria interventions has increased dramatically in countries where the Global Fund invests. In 2025, 80% of people living with HIV were receiving antiretroviral therapy, up from 22% in 2010. TB treatment coverage reached 79% in 2024, compared with 44% in 2010. Access to long-lasting insecticide-treated nets also increased, with 55% of the population covered in 2024, up from 29% in 2010.
Progress in prevention, testing, treatment and care has contributed to significant reductions in mortality from all three diseases and remains critical to reaching global health targets. Despite severe financial pressures and other shocks, countries and partners worked to protect essential services and preserve many of these hard-won gains, demonstrating the resilience of the Global Fund partnership. These results underscore why investment in the Global Fund remains one of the most effective ways to save lives, improve health outcomes in the most vulnerable communities, and reinforce global health security.
Yet the disruptions experienced in 2025 also highlighted the fragility of global progress against the three diseases. Continued gains will depend on protecting access to essential services while ensuring countries can sustainably finance and deliver them without external support in the future.
Our results reflect the contributions of a wide range of actors across the Global Fund partnership, including governments, multilateral, regional and bilateral partners, the private sector, civil society organizations, and the people and communities affected by the three diseases.
Coverage of treatment and prevention interventions
Malaria coverage is calculated based on 38 African countries where the Global Fund invests, for which data is available from World Health Organization (WHO)/Malaria Atlas Project estimates. HIV and TB estimates are based on countries that have recently received Global Fund funding and have reported programmatic results over the past two cycles. Based on published data from WHO (2025 release for TB and malaria) and UNAIDS (2026 release for HIV). Global Fund Regional Groupings.
2026 Results Report
HIV: State of the Fight
Key HIV results in 2025 in countries where the Global Fund invests:
Programmatic results achieved during 2025 by countries and regions where the Global Fund invests. Global Fund Regional Groupings.
In 2025, the fight against HIV shifted sharply from momentum to uncertainty. Funding disruptions affected prevention programs, community-led services and outreach activities across many countries. Testing and prevention services were scaled back in some settings, increasing risks for populations already facing the greatest barriers to care.
Despite these challenges, countries and communities moved rapidly to protect HIV treatment services and maintain access to care. The Global Fund partnership worked closely with countries to reprioritize investments, sustain high-impact programs and support people living with HIV to continue receiving lifesaving treatment.
The Global Fund supported countries to protect HIV prevention and testing services, prioritizing people and communities at greatest risk of HIV infection. Our investments expanded prevention options, including condoms and a diverse set of pre-exposure prophylaxis (PrEP) tools, alongside the first rollout of breakthrough prevention medicine lenacapavir in early-adopter countries. Countries broadened community-based HIV testing, integrated testing with primary healthcare, and increased the use of HIV self-testing to reach more people. Together, these efforts helped sustain testing despite funding cuts, with 12.1 million HIV tests taken by priority and key populations in 2025 in countries where the Global Fund invests.
People living with HIV who know their status
People living with HIV receiving ARVs
People living with HIV with suppressed viral load
Prevention of mother-to-child transmission coverage
All data is based on estimates from the UNAIDS 2026 release. Global Fund disbursements are available on the Global Fund Data Explorer. The denominator for the three 95s is people living with HIV. The data for disease burden estimate and service coverage reflects the data available from UNAIDS at the time of publication. Global Fund Regional Groupings.
Protecting uninterrupted access to treatment remained a top priority. In 2025, 26.9 million people were on lifesaving antiretroviral therapy in countries where the Global Fund invests. The Global Fund also supported improved care for people with advanced HIV disease and accelerated the rollout of optimized pediatric HIV treatment.
Alongside protecting essential services, the Global Fund continued to strengthen the long-term sustainability of HIV programs. Countries integrated HIV services into broader health systems and expanded community-led service delivery, making care more accessible. Optimized treatment regimens and innovative market-shaping approaches are helping countries deliver greater impact with fewer resources.
The HIV innovation pipeline is broadening rapidly, with the next wave of tools designed to increase choice, simplify delivery and make prevention, testing and treatment more sustainable over the long term. In 2025, the Global Fund helped accelerate the rollout of lenacapavir, the first HIV prevention innovation to reach high-income and low- and middle-income countries in the same year. By working with countries, communities, manufacturers and partners to improve affordability and strengthen delivery systems, our partnership is helping ensure this breakthrough reaches the people who need it most.
Access for everyone
In 2025, HIV prevention, testing and treatment services for key and vulnerable populations were disrupted in a number of countries where the Global Fund invests, while new laws and policies in some countries further increased barriers to accessing care. Against this backdrop, the Global Fund continued to invest in community-led responses that help people access HIV services and address the stigma, discrimination and human rights barriers to health that can undermine progress.
Through the Breaking Down Barriers initiative, investments supported community-led monitoring to identify human rights-related barriers in health facilities, with referrals to legal services and other interventions to address barriers at both the facility and community level. The Global Fund also supported advocacy to improve health-related laws, regulations and policies and strengthen access to HIV care. At the same time, HIV prevention efforts continued to focus on people at greatest risk of acquiring HIV, including key populations and adolescent girls and young women, with community-led responses playing a critical role in reaching and supporting those most affected.
Reduction in HIV incidence rate among women aged 15-24
HIV burden estimates from UNAIDS, 2026 release.
Trends in HIV Burden
Between 2002 and 2025, AIDS-related deaths dropped by 77% and new HIV infections by 64% in countries where the Global Fund invests. With no prevention or treatment, infections would have risen by an estimated 77% and deaths by 98% over the same period. The AIDS-related mortality rate was down 84% and the incidence rate declined by 75% over the same period. Yet progress must accelerate: Current reductions are not sufficient to get on track for the 90% reduction in new infections and AIDS-related deaths by 2030.
Trends in AIDS-related deaths
Trends in new HIV infections
HIV burden estimates from UNAIDS, 2026 release. Estimation of “no prevention or ARVs” trends from Goals and AIM models where available. For some countries estimates of burden are not available from UNAIDS. Global Fund portfolio indicates countries that have recently received Global Fund HIV and AIDS funding and have reported programmatic results over the past two cycles. Global Fund Regional Groupings.
Investing for Sustainable Impact
The Global Fund provides 28% of all international financing for HIV programs. Since 2002, we have invested US$28.5 billion in HIV programs and US$9.6 billion in HIV/TB programs, as of 30 June 2026. Global Fund investments in HIV support long-term sustainability by strengthening health and community systems, enabling countries to sustain essential services, protect hard-won gains and respond to future health threats.
Progress Towards the Global Targets
Working with partners, the Global Fund has supported many countries to reach the UNAIDS 95-95-95 targets – where 95% of people living with HIV know their status, 95% of those who know their status are on treatment, and 95% of those on treatment achieve viral suppression. Eight countries where the Global Fund invests have already achieved the targets: Botswana, Cambodia, Eswatini, Lesotho, Namibia, Rwanda, Zambia and Zimbabwe. But progress remains fragile and the deep rifts in the HIV response in 2025 put this incredible progress at risk.
The HIV response stands at a pivotal moment: Promising innovations have the potential to transform the fight, but hard-won gains could be lost without sustained action. Continued investment and commitment will be essential to build on progress, ensure equitable access to new tools and approaches, and reach the people who need them most.
People living with HIV on antiretroviral therapy
In countries where the Global Fund invests
Source: UNAIDS 2026 release. People on antiretroviral therapy reported to UNAIDS in countries supported by the Global Fund over the past two funding cycles. Programmatic results published in other parts of this report are based primarily on data reported to the Global Fund in 2025, according to the grant reporting cycle.
AIDS-related deaths: Progress towards the UNAIDS target
New HIV infections: progress towards the UNAIDS target
“Continuation of recent trend” projection is based on recent trends (10 years). “Global target pathway to 2030” is based on the target from UNAIDS 2025 targets to end AIDS, 2021 update. Countries that have recently received Global Fund HIV and AIDS funding and have reported programmatic results over the past two cycles. Global Fund Regional Groupings. Based on published data from UNAIDS 2026 release. Portfolio and regional aggregations include countries with a UNAIDS target.
Tuberculosis: State of the Fight
Key TB results in 2025 in countries where the Global Fund invests:
Programmatic results achieved during 2025 by countries and regions where the Global Fund invests. Global Fund Regional Groupings.
In 2025, funding cuts and multiple overlapping crises placed new pressure on TB programs, threatening progress made in recent years. Countries faced disruptions across prevention, diagnosis and treatment services, straining national TB programs. Yet despite these challenges, countries and partners demonstrated resilience. The Global Fund partnership worked with countries to protect essential TB services, prioritize lifesaving interventions and adopt more efficient approaches to care, helping safeguard progress against the world’s deadliest infectious disease.
Preventing TB remains one of the most effective ways to reduce illness, save lives and lower long-term costs. In 2025, the Global Fund supported countries to protect and expand TB prevention by prioritizing people at highest risk, including people living with HIV and household contacts of people with TB, especially children under 5. Investments in shorter, WHO-recommended preventive treatment regimens, stronger contact tracing and integrated active case-finding strategies helped countries reach people while making services more efficient and sustainable.
The Global Fund also supported countries to find, diagnose and treat TB earlier through more focused, people-centered approaches. Investments in community-based screening, rapid molecular diagnostics, AI-enabled digital chest X-rays, shorter treatment regimens and integrated service delivery are helping countries detect TB faster, improve outcomes and reduce costs. By strengthening laboratory, community and digital systems, our partnership is helping build more resilient TB programs.
Children and adolescents continue to bear a significant share of the global TB burden. The Global Fund supports countries to expand access to child-friendly prevention, diagnosis and treatment through improved diagnostics, pediatric treatment formulations, shorter treatment regimens and family-centered models of care. These investments are helping more children receive timely, lifesaving care while strengthening national TB programs.
Innovation is creating new opportunities to accelerate progress. The Global Fund has expanded the rollout of AI-enabled digital X-rays to over 20 countries. We are also supporting near-point-of-care molecular tests that can deliver accurate results in under an hour, enabling earlier treatment while expanding access in remote and underserved communities. With support from the Global Fund and partners, 13 countries are introducing these next-generation diagnostics, aiming to deliver nearly 3 million tests by the end of 2026. By helping countries rapidly adopt and scale new technologies, our partnership is accelerating equitable access to innovation while strengthening more efficient and sustainable TB programs.
TB treatment coverage
TB treatment success rate
MDR-TB treatment success rate
HIV+ TB patients on ARVs
All data are based on estimates from Global Tuberculosis Report 2025. Global Fund disbursements are available on the Global Fund Data Explorer. Global Fund Regional Groupings
Trends in TB Burden
Through close collaboration with governments, health workers, civil society, affected communities and the private sector, the Global Fund partnership has helped transform the fight against TB. Between 2002 and 2024, TB deaths fell by 43%; without these efforts, deaths would have increased by an estimated 121% and TB cases by 44%, in countries where the Global Fund invests. Over the same period, the TB mortality rate declined by 60% and the incidence rate by 33% in countries where the Global Fund invests.
Trends in TB deaths (excluding HIV-positive)
Trends in new TB cases (all forms)
TB burden estimates from WHO Global TB Report 2025. Estimation of “no TB control” trends for TB deaths from WHO and for new TB cases based on the assumption of constant trend in new TB cases since 2000. While major control efforts for malaria and HIV began with the launch of the Millennium Development Goals in 2000, TB control efforts began much earlier. The counter-factual and actual results therefore diverged from each other much earlier, making this graph look considerably different than its HIV and malaria counterparts. Global Fund portfolio indicates countries that have recently received Global Fund TB funding and have reported programmatic results over the past two cycles. Global Fund Regional Groupings.
Investing for Sustainable Impact
The Global Fund provides 80% of all international financing for TB. As of 30 June 2026, the Global Fund had invested US$10.9 billion in programs to prevent and treat TB and an additional US$9.6 billion in TB/HIV and other cross-disease programs since 2002.
Global Fund investments in TB are helping build more sustainable health systems by strengthening laboratories, diagnostic networks, supply chains, health workers and community systems that support multiple health priorities. Years of integrating TB services with HIV, primary healthcare and broader disease programs have enabled countries to improve efficiency, build resilience and sustain essential services.
Progress Towards the Global Targets
The world has the tools needed to end TB as a public health threat, but progress must accelerate.
Over the last two decades, countries supported by the Global Fund partnership have expanded access to TB prevention, diagnosis and treatment at unprecedented scale. Millions more people are receiving lifesaving services, and countries continue to adopt innovations that improve outcomes and strengthen sustainability.
However, TB remains the world’s deadliest infectious disease killer, and progress is fragile. Sustained investment, strong country leadership, community engagement and rapid adoption of new technologies will be essential to close remaining gaps and get the world on track toward ending TB as a public health threat.
People treated for TB
In countries where the Global Fund invests
TB treatment coverage can be approximated as the annual number of people newly diagnosed with TB and officially reported as a TB case divided by the estimated number of people who developed TB (incident cases) in the same year, expressed as a percentage. The data is from the WHO Global Tuberculosis Report 2025, in countries supported by the Global Fund over the past two funding cycles. Programmatic results published in other parts of this report are based primarily on data reported to the Global Fund in 2025.
TB deaths: progress towards the WHO target*
TB incidence rate: progress towards the WHO target
* TB deaths include deaths among HIV-positive people. “Continuation of recent trend” projection is based on the based on recent trends (10 years), excluding years affected by COVID-19. “Global target pathway to 2030” is based on targets from the WHO End TB Strategy. Countries that have recently received Global Fund TB funding and have reported programmatic results over the past two cycles. Global Fund Regional Groupings. Based on published data from the Global Tuberculosis Report 2025.
Malaria: State of the Fight
Key malaria results in 2025 in countries where the Global Fund invests:
Programmatic results achieved during 2025 by countries and regions where the Global Fund invests. Global Fund Regional Groupings.
In 2025, the fight against malaria became more precarious than at any point in recent years. Drug and insecticide resistance, conflict, displacement and climate-related shocks intensified transmission risks, while funding disruptions placed additional strain on already overstretched malaria programs. Many countries reported stock-outs of essential medicines and delays to time-sensitive interventions such as vector control and seasonal malaria chemoprevention, threatening to reverse hard-won gains.
Despite these challenges, countries and partners acted quickly to protect the highest-impact interventions. The Global Fund supported countries to reprioritize investments, sustain essential services and strengthen more resilient and sustainable malaria programs in the face of growing challenges. Efforts focused on guiding strategic funding decisions across case management and prevention, identifying the most efficient delivery approaches and prioritizing malaria interventions for populations at greatest risk, including those living in hard-to-reach and conflict-affected settings.
Mosquito nets population coverage
Mosquito nets population use
Suspected malaria cases tested
All data are based on estimates from World Malaria Report 2025. Global Fund disbursements are available on the Global Fund Data Explorer. Global Fund Regional Groupings
Preventing malaria remains the most effective way to reduce illness and save lives. In 2025, the Global Fund supported countries to protect prevention services by prioritizing the distribution of insecticide-treated mosquito nets, seasonal malaria chemoprevention and preventive treatment for pregnant women, while strengthening community-based delivery and integrating malaria prevention into antenatal and primary healthcare services. As insecticide resistance continues to threaten progress, the Global Fund is accelerating access to next-generation vector control tools, including dual active-ingredient insecticide-treated mosquito nets, using innovative financing approaches to make these more affordable and accessible.
Prompt diagnosis and effective treatment are essential to reducing malaria deaths and limiting transmission. The Global Fund supported countries to sustain access to rapid diagnosis and effective treatment, strengthen community-based case management and improve the quality of care in high-burden settings. At the same time, we are working with countries and partners to respond to growing antimalarial drug resistance by expanding access to multiple first-line therapies to diversify treatment options.
The Global Fund is supporting countries to prepare for the next generation of malaria tools and strengthening the systems needed to deliver them effectively. Through market-shaping initiatives such as the Access Fund, our partnership is making innovative medicines and tools more affordable and accelerating their introduction. For instance, we are supporting the procurement of spatial repellents – one of the first new categories of malaria vector control tools in 25 years to receive a conditional WHO recommendation for malaria prevention. Spatial repellents complement existing tools like insecticide-treated nets and indoor residual spraying and can further reduce malaria transmission when used together.
Trends in Malaria Burden
In countries where the Global Fund invests, malaria deaths reduced by 27% between 2002 and 2024, even though the population at risk for malaria in these countries increased by 48%. Between 2002 and 2024, malaria cases in countries supported by the Global Fund increased by 16%. Without malaria control measures, cases would have increased by an estimated 85% and deaths by an estimated 99% over the same period. Between 2002 and 2024, the malaria incidence rate in countries supported by the Global Fund dropped by 22%, and the malaria mortality rate dropped by 51%.
Trends in malaria deaths
Trends in malaria cases
Malaria burden estimates and estimation of “no malaria control” from WHO Global Malaria Programme, 2025 release. Global Fund portfolio indicates countries that have recently received Global Fund malaria funding and have reported programmatic results over the past two cycles. Global Fund Regional Groupings.
Investing for Sustainable Impact
The Global Fund partnership provides 57%1 of all international financing for malaria programs and, since 2002, has invested US$21.4 billion in the fight against malaria, as of 30 June 2026. Because the burden of malaria is concentrated in fragile and conflict-affected settings, the largest share of Global Fund malaria investments supports countries facing humanitarian crises. Predictable, long-term financing helps countries plan and deliver time-sensitive interventions, maintain access to essential commodities and protect hard-won gains against a disease that can quickly resurge when investments falter.
Progress Towards the Global Targets
Countries have made significant gains against malaria over the past two decades, but progress has stalled, leaving millions of people – particularly children – at continued risk.
Regaining momentum will require sustained investment, innovation and stronger health systems. New medicines, diagnostics, vector control tools and smarter delivery approaches offer important opportunities to accelerate progress, but their impact depends on strong, sustainable health and community systems that can deliver these innovations equitably and at scale.
Despite the growing challenges, countries continue to demonstrate that ending malaria is achievable. The Global Fund is supporting elimination efforts in 21 countries across Asia, Africa and Latin America. In 2025, Georgia, Suriname and Timor-Leste were certified malaria-free by WHO, demonstrating that with sustained investment, strong national leadership and effective prevention, diagnosis and treatment, countries can eliminate malaria and protect those gains over the long term.
People with access to an insecticide-treated mosquito net
In sub-Saharan African countries where the Global Fund invests
Source: WHO/Malaria Atlas Project estimates 2025 (38 African countries for which data is available).
Malaria mortality rate: progress towards the WHO target
Malaria incidence rate: progress towards the WHO target
“Continuation of recent trend” projection is based on recent trends (10 years), excluding years affected by COVID-19. “Global target pathway to 2030” is based on targets from the WHO Global Technical Strategy for Malaria (2021 update). Countries that have recently received Global Fund malaria funding and have reported programmatic results over the past two cycles. Global Fund Regional Groupings. Based on published data from World Malaria Report 2025.
Health and Community Systems
Progress against HIV, TB and malaria depends on strong, resilient health and community systems that can deliver integrated, people-centered care.
Between 2024 and 2026, the Global Fund is investing approximately US$5.9 billion2 in health and community systems – a 43% increase over the previous grant cycle and the largest health systems investment in our history. These investments are strengthening laboratories, disease surveillance, the health workforce, community systems, oxygen infrastructure, supply chains and digital health, while building countries’ capacity to prevent, detect and respond to a broad range of infectious diseases.
Our investments help sustain effective HIV, TB and malaria responses and address wider health threats, including outbreaks and antimicrobial resistance. Investments in laboratories, diagnostics and surveillance support responses to diseases such as Ebola, mpox and Marburg virus disease, as well as the detection and management of co-infections including hepatitis B and C and human papillomavirus. The Global Fund also provides emergency funding to help countries respond rapidly to disease outbreaks and other public health emergencies.
As countries move toward greater self-reliance, the Global Fund is supporting national capacity and country-led priorities to build more sustainable health systems. These investments strengthen core public health capacities, improving health outcomes today while enhancing global health security against future health threats.
Shaping Markets for Sustainable Access
As countries take on greater responsibility for financing and procuring health products, the Global Fund is using its purchasing power and market-shaping expertise to help lower prices, strengthen supply security and make health products more affordable and sustainable over time. We are working with countries, manufacturers and regional procurement platforms to aggregate demand, strengthen procurement capacity and create more predictable markets.
In 2025, US$1.02 billion in health products were ordered through the Global Fund’s Pooled Procurement Mechanism, which pools demand from more than 80 countries and uses our scale to negotiate competitive prices and supply terms. Since 2018, countries have also used non-Global Fund resources to procure US$128 million in health products through the platform, extending the benefits of our purchasing power beyond Global Fund financing. At the same time, we are supporting regional manufacturers to meet quality and procurement requirements and expanding access to products manufactured closer to where they are needed. Together, these efforts help countries stretch available resources further, strengthen regional markets and build more sustainable access to affordable, quality-assured health products.
Investing for Sustainable Impact
Since 2002, the Global Fund partnership has invested US$73.7 billion3 to support countries in the fight against HIV, TB and malaria while strengthening the health and community systems that underpin long-term progress. In 2025, the Global Fund disbursed US$3.9 billion in total. At the heart of our model is country ownership: Countries define their own priorities, with governments, communities and civil society leading the design and implementation of programs. By investing in high-impact interventions, strengthening national systems and supporting domestic leadership, the Global Fund supports countries to build the capacity to sustain progress long after external financing ends.
Maximizing the impact of every dollar is increasingly important in a constrained financing environment. The Global Fund combines predictable grant financing with innovative approaches that mobilize additional resources, accelerate access to new tools and strengthen health systems. Through catalytic investments, blended finance, debt swaps and strategic partnerships with governments, philanthropies, the private sector and multilateral development banks, our partnership is supporting countries to scale proven innovations, improve efficiency and strengthen the long-term sustainability of national HIV, TB and malaria responses.
As countries move toward greater self-reliance, the Global Fund is supporting a sustainable transition to nationally financed and nationally led health programs. Through co-financing, public financial management, domestic resource mobilization and tailored transition planning, we are supporting countries to achieve improved domestic investment in health, strengthen national institutions and integrate disease programs into broader health systems. This country-led approach is helping ensure that progress against HIV, TB and malaria can be sustained while building stronger, more resilient health systems that improve health security and are better prepared to respond to future health threats.
Our Results Methodology
The Global Fund Results Report 2026 presents selected programmatic results (e.g., people on antiretroviral therapy, people treated for TB, mosquito nets distributed) achieved by supported programs in 2025. The programmatic results are reported routinely to the Global Fund by the supported programs. The data collected by our technical partners are also used for cross-checking and triangulation and for furnishing national data for selected services to align with the Global Fund partnership’s approach to results reporting. The Global Fund also uses official disease burden and impact estimates developed and published by our technical partners, including WHO and UNAIDS, as the basis for measuring coverage, outcome and impact.
[1] For malaria, the Results Report uses international financing data from 2024, the latest data available. Recent shifts in international financing for malaria may significantly impact the Global Fund’s share of overall international malaria financing.
[2] Based on approved and signed budgets for Grant Cycle 7 and including C19RM. It integrates direct investments in resilient and sustainable systems for health (direct RSSH) and contributions to RSSH through investments in the fight against AIDS, TB and malaria (contributory RSSH). It excludes catalytic investments and Secretariat Operating expenses.